X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (10724) 10724
Magazine Article (29) 29
Book Chapter (5) 5
Newspaper Article (4) 4
Conference Proceeding (3) 3
Book / eBook (2) 2
Book Review (2) 2
Dissertation (2) 2
Newsletter (2) 2
Publication (2) 2
Web Resource (2) 2
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (7909) 7909
pyrazoles - therapeutic use (5831) 5831
male (4630) 4630
animals (3913) 3913
female (3726) 3726
pyrazoles - pharmacology (3435) 3435
middle aged (2226) 2226
celecoxib (2095) 2095
aged (2025) 2025
pharmacology & pharmacy (1959) 1959
adult (1801) 1801
pyrazoles - administration & dosage (1682) 1682
oncology (1666) 1666
mice (1662) 1662
pyrazoles - adverse effects (1635) 1635
rats (1497) 1497
sulfonamides - therapeutic use (1442) 1442
treatment outcome (1376) 1376
hematology (973) 973
dose-response relationship, drug (949) 949
cancer (923) 923
pyrazoles (923) 923
pyridines - therapeutic use (887) 887
protein kinase inhibitors - therapeutic use (871) 871
pyridones - therapeutic use (856) 856
pyrimidines - therapeutic use (832) 832
antineoplastic agents - therapeutic use (805) 805
analysis (802) 802
piperidines - pharmacology (771) 771
administration, oral (759) 759
care and treatment (753) 753
aged, 80 and over (745) 745
cell line, tumor (742) 742
expression (739) 739
anticoagulants - therapeutic use (706) 706
pyrazoles - chemistry (679) 679
neurosciences (667) 667
disease models, animal (657) 657
sulfonamides - pharmacology (653) 653
research (643) 643
rivaroxaban (625) 625
cyclooxygenase inhibitors - therapeutic use (622) 622
abridged index medicus (617) 617
drug therapy (612) 612
anti-inflammatory agents, non-steroidal - therapeutic use (606) 606
dabigatran (599) 599
time factors (592) 592
medicine, general & internal (584) 584
pyrimidines - pharmacology (581) 581
lung neoplasms - drug therapy (575) 575
rats, sprague-dawley (574) 574
risk factors (564) 564
apoptosis (563) 563
sulfonamides - adverse effects (556) 556
piperidines - therapeutic use (554) 554
chemistry, medicinal (549) 549
pyrazoles - pharmacokinetics (520) 520
anticoagulants (515) 515
receptor, cannabinoid, cb1 - antagonists & inhibitors (514) 514
mutation (513) 513
clinical trials as topic (511) 511
medicine & public health (506) 506
activation (505) 505
health aspects (500) 500
double-blind method (496) 496
warfarin (487) 487
biochemistry & molecular biology (486) 486
therapy (485) 485
nonsteroidal antiinflammatory drugs (482) 482
apixaban (477) 477
chemotherapy (472) 472
sulfonamides - administration & dosage (471) 471
cell biology (454) 454
inhibition (449) 449
antineoplastic agents - pharmacology (445) 445
pharmacology/toxicology (443) 443
atrial fibrillation - drug therapy (439) 439
carcinoma, non-small-cell lung - drug therapy (439) 439
adolescent (433) 433
safety (433) 433
antineoplastic combined chemotherapy protocols - therapeutic use (429) 429
cyclooxygenase 2 inhibitors - therapeutic use (425) 425
prevention (425) 425
kinases (423) 423
protein kinase inhibitors - pharmacology (423) 423
signal transduction - drug effects (422) 422
clinical trials (419) 419
cox-2 inhibitors (419) 419
inhibitors (418) 418
efficacy (417) 417
cell proliferation - drug effects (413) 413
rats, wistar (411) 411
apoptosis - drug effects (406) 406
stroke - prevention & control (401) 401
inflammation (396) 396
pyridines - pharmacology (396) 396
patients (395) 395
pyridones - adverse effects (386) 386
risk (380) 380
tumors (379) 379
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (9932) 9932
German (292) 292
French (155) 155
Japanese (109) 109
Italian (105) 105
Spanish (87) 87
Chinese (52) 52
Russian (40) 40
Polish (26) 26
Czech (24) 24
Portuguese (18) 18
Swedish (11) 11
Danish (10) 10
Hungarian (9) 9
Norwegian (8) 8
Dutch (7) 7
Finnish (4) 4
Croatian (3) 3
Romanian (3) 3
Serbian (2) 2
Slovak (2) 2
Bulgarian (1) 1
Korean (1) 1
Lithuanian (1) 1
Turkish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Thrombosis and Haemostasis, ISSN 0340-6245, 09/2015, Volume 113, Issue 5, pp. 931 - 942
Summary Several new anticoagulants have entered the clinical arena or are under clinical development. These drugs include indirect (fondaparinux) and direct... 
Review Article | Rivaroxaban | Antidotes | Dabigatran | New anticoagulants | Apixaban | ANDEXANET-ALPHA | VITAMIN-K ANTAGONISTS | rivaroxaban | apixaban | ATRIAL-FIBRILLATION | antidotes | IN-VITRO | ANTIIDIOTYPIC ANTIBODIES | PROTHROMBIN COMPLEX CONCENTRATE | ORAL ANTICOAGULANTS | MOLECULAR-WEIGHT HEPARIN | dabigatran | PERIPHERAL VASCULAR DISEASE | HEALTHY-VOLUNTEERS | HEMATOLOGY | ACUTE VENOUS THROMBOEMBOLISM | Recombinant Proteins - therapeutic use | Pyrazoles - therapeutic use | Anticoagulants - administration & dosage | Thrombosis - complications | Humans | Antibodies, Monoclonal - therapeutic use | Heparin - therapeutic use | Hemorrhage - prevention & control | Thiazoles - therapeutic use | Dabigatran - therapeutic use | Vitamin K - antagonists & inhibitors | Benzamides - therapeutic use | Anticoagulants - chemistry | Factor Xa - therapeutic use | Intracranial Hemorrhages - prevention & control | Rivaroxaban - therapeutic use | Pyridines - therapeutic use | Polysaccharides - therapeutic use | Hemostatics - chemistry | Antibodies, Monoclonal, Humanized - therapeutic use | Administration, Oral | Antithrombins - therapeutic use | Infusions, Parenteral | Clinical Trials as Topic | Factor Xa Inhibitors - therapeutic use | Animals | Protamines - therapeutic use | Pyridones - therapeutic use | Thrombosis - drug therapy | Hemorrhage - chemically induced | Hemostatics - therapeutic use
Journal Article
Circulation, ISSN 0009-7322, 07/2016, Volume 134, Issue 3, pp. 248 - 261
Vitamin K antagonists are commonly used by clinicians to provide anticoagulation to patients who have or are at risk of having thrombotic events. In addition... 
anticoagulants | atrial fibrillation | venous thromboembolism | hemorrhage | CARDIAC & CARDIOVASCULAR SYSTEMS | ACTIVATED FACTOR-VII | ATRIAL-FIBRILLATION | IN-VITRO | THROMBIN GENERATION | DABIGATRAN ETEXILATE | PROTHROMBIN COMPLEX CONCENTRATE | SYMPTOMATIC VENOUS THROMBOEMBOLISM | PRACTICAL MANAGEMENT | PERIPHERAL VASCULAR DISEASE | STAGE RENAL-DISEASE | FACTOR XA INHIBITOR | Recombinant Proteins - therapeutic use | Plasma | Dabigatran - adverse effects | Pyrazoles - therapeutic use | Humans | Hemorrhage - prevention & control | Recombinant Proteins - adverse effects | Thiazoles - therapeutic use | Factor VIIa - therapeutic use | Arginine - analogs & derivatives | Dabigatran - therapeutic use | Thiazoles - adverse effects | Pyridines - adverse effects | Rivaroxaban - adverse effects | Factor Xa - therapeutic use | Rivaroxaban - therapeutic use | Factor Xa - adverse effects | Pyrazoles - adverse effects | Pyridines - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Administration, Oral | Antithrombins - therapeutic use | Piperazines - therapeutic use | Dabigatran - antagonists & inhibitors | Piperazines - adverse effects | Factor Xa Inhibitors - therapeutic use | Hemorrhage - drug therapy | Antithrombins - adverse effects | Factor Xa Inhibitors - adverse effects | Blood Coagulation Factors - therapeutic use | Arginine - adverse effects | Pyridones - therapeutic use | Hemorrhage - chemically induced | Hemostatics - therapeutic use | Arginine - therapeutic use | Pyridones - adverse effects
Journal Article
Journal Article
Journal Article
PloS one, ISSN 1932-6203, 2018, Volume 13, Issue 6, p. e0198184
... of splenectomy (Splx) as the first and still successfully used therapeutic measure in management of immune thrombocytopenia (ITP) [1]. The second therapeutic measure... 
AUTOIMMUNE THROMBOCYTOPENIA | TREATMENT OPTIONS | ADULT PATIENTS | INTRAVENOUS GAMMA-GLOBULIN | MANAGEMENT | ANTI-D | MEDICAL THERAPY | SAFETY | PURPURA | ROMIPLOSTIM | MULTIDISCIPLINARY SCIENCES | Prednisolone - adverse effects | Azathioprine - therapeutic use | Pyrazoles - therapeutic use | Benzoates - therapeutic use | Recombinant Fusion Proteins - adverse effects | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Immunoglobulins, Intravenous - adverse effects | Child, Preschool | Dexamethasone - adverse effects | Male | Dapsone - therapeutic use | Purpura, Thrombocytopenic, Idiopathic - drug therapy | Receptors, Fc - therapeutic use | Splenectomy | Young Adult | Aged, 80 and over | Child | Rituximab - adverse effects | Purpura, Thrombocytopenic, Idiopathic - surgery | Combined Modality Therapy | Remission Induction | Cyclosporine - therapeutic use | Dexamethasone - therapeutic use | Immunoglobulins, Intravenous - therapeutic use | Rho(D) Immune Globulin - adverse effects | Cyclosporine - adverse effects | Adolescent | Rho(D) Immune Globulin - therapeutic use | Dapsone - adverse effects | Benzoates - adverse effects | Recombinant Fusion Proteins - therapeutic use | Thrombopoietin - therapeutic use | Purpura, Thrombocytopenic, Idiopathic - therapy | Rituximab - therapeutic use | Adult | Female | Prednisolone - therapeutic use | Retrospective Studies | Drug Therapy, Combination | Drug Resistance | Pyrazoles - adverse effects | Hydrazines - therapeutic use | Treatment Outcome | Thrombopoietin - adverse effects | Immunosuppressive Agents - adverse effects | Aged | Azathioprine - adverse effects | Hydrazines - adverse effects | Thrombocytopenic purpura | Clinical trials | Treatment outcome | Care and treatment | Analysis | Drugs | Thrombocytopenia | Therapy | Immunoglobulins | Dexamethasone | Intravenous administration | Medical treatment | Patients | Immunosuppressive agents | Bleeding | Medicine | Remission | Clinical medicine | Azathioprine | Drug dosages | Prednisolone
Journal Article
The Journal of Bone & Joint Surgery, ISSN 0021-9355, 02/2013, Volume 95, Issue 4, pp. 291 - 296
.... Although multimodal pain management is commonly used for pain control for patients undergoing elective surgery, few studies have evaluated its use in those undergoing hip fracture surgery... 
KNEE | SURGERY | DEMENTIA | TOTAL JOINT ARTHROPLASTY | DELIRIUM | HOSPITAL STAY | LOCAL INFILTRATION ANALGESIA | ELDERLY PATIENTS | ORTHOPEDICS | PUMP | CONSUMPTION | POSTOPERATIVE PAIN | Fentanyl - administration & dosage | Single-Blind Method | Hip Fractures - surgery | Pyrazoles - therapeutic use | Prospective Studies | Fentanyl - therapeutic use | Humans | Male | Adrenergic alpha-Agonists - therapeutic use | Arthroplasty, Replacement, Hip - methods | Adrenergic alpha-Agonists - administration & dosage | Epinephrine - therapeutic use | Cyclooxygenase 2 Inhibitors - therapeutic use | Statistics, Nonparametric | Aged, 80 and over | Anesthetics, Local - therapeutic use | Anesthetics, Local - administration & dosage | Oxycodone - therapeutic use | Oxycodone - administration & dosage | Cyclooxygenase 2 Inhibitors - administration & dosage | Pain Management - methods | Analgesics, Opioid - therapeutic use | Anti-Bacterial Agents - administration & dosage | Morphine - administration & dosage | Sulfonamides - administration & dosage | Ketorolac - therapeutic use | Pain, Postoperative - drug therapy | Epinephrine - administration & dosage | Patient Satisfaction | Anti-Bacterial Agents - therapeutic use | Cefmetazole - therapeutic use | Female | Drug Therapy, Combination | Analgesia, Patient-Controlled | Treatment Outcome | Amides - therapeutic use | Celecoxib | Chi-Square Distribution | Pyrazoles - administration & dosage | Sulfonamides - therapeutic use | Analgesics, Opioid - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Injections, Intra-Articular | Aged | Ketorolac - administration & dosage | Pain Measurement | Amides - administration & dosage | Morphine - therapeutic use | Cefmetazole - administration & dosage
Journal Article
Journal Article
Journal of thrombosis and haemostasis, ISSN 1538-7933, 2018, Volume 16, Issue 9, pp. 1891 - 1894
...) monotherapy for at least 3–6 months, owing to the lack of cancer‐specific data regarding the use of these agents . Both recent emerging data from clinical practice... 
PROPHYLAXIS | THERAPY | THROMBOSIS | SAFETY | DISEASE | PREVENTION | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | GUIDELINE | Recurrence | Pulmonary Embolism - prevention & control | Pyrazoles - therapeutic use | Dabigatran - administration & dosage | Prospective Studies | Anticoagulants - administration & dosage | Humans | Thiazoles - administration & dosage | Antithrombins - administration & dosage | Thiazoles - therapeutic use | Dabigatran - therapeutic use | Rivaroxaban - administration & dosage | Venous Thromboembolism - drug therapy | Factor Xa Inhibitors - administration & dosage | Neoplasms - complications | Pyridones - administration & dosage | Venous Thromboembolism - prevention & control | Multicenter Studies as Topic | Neoplasms - blood | Dalteparin - therapeutic use | Observational Studies as Topic | Venous Thrombosis - prevention & control | Rivaroxaban - therapeutic use | Pyridines - therapeutic use | Pyridines - administration & dosage | Venous Thrombosis - drug therapy | Administration, Oral | Antithrombins - therapeutic use | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Venous Thrombosis - etiology | Randomized Controlled Trials as Topic | Venous Thromboembolism - etiology | Factor Xa Inhibitors - therapeutic use | Pyrazoles - administration & dosage | Patient Acceptance of Health Care | Pulmonary Embolism - etiology | Antithrombins - adverse effects | Factor Xa Inhibitors - adverse effects | Pulmonary Embolism - drug therapy | Pyridones - therapeutic use | Hemorrhage - chemically induced | Care and treatment | Anticoagulants (Medicine) | Thromboembolism | Drug therapy | Cancer | Anticoagulants
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 02/2018, Volume 2019, Issue 4, p. CD004121
Background This is an updated version of the original Cochrane review published in 2014, Issue 4. Cervical intraepithelial neoplasia (CIN) precedes the... 
Uterine Cervical Neoplasms | Administration, Oral | Anti‐Inflammatory Agents, Non‐Steroidal | CANCER OF THE UTERINE CERVIX | Induction Chemotherapy | Celecoxib | Cervix | Disease Progression | Lactones | Randomized Controlled Trials as Topic | Gynaecology | Cyclooxygenase 2 Inhibitors | Sulfonamides | Gynaecological | Placebos | Medicine General & Introductory Medical Sciences | Cervical Intraepithelial Neoplasia | Sulfones | Strategies and implementation for pre‐malignant changes | Cancer | COX-2 | Sulfones [administration & dosage; therapeutic use] | Humans | Sulfonamides [administration & dosage; therapeutic use] | COLON-CANCER | MEDICINE, GENERAL & INTERNAL | PHASE-II TRIAL | CHEMOPREVENTIVE ACTIVITY | TRANSITIONAL-CELL CARCINOMA | Pyrazoles [administration & dosage; therapeutic use] | Female | Lactones [administration & dosage; therapeutic use] | INHIBITOR | UP-REGULATION | Uterine Cervical Neoplasms [drug therapy] | Induction Chemotherapy [methods] | DOUBLE-BLIND | Cyclooxygenase 2 Inhibitors [administration & dosage; therapeutic use] | CYCLOOXYGENASE-2 EXPRESSION | Anti-Inflammatory Agents, Non-Steroidal [administration & dosage; therapeutic use] | Cervical Intraepithelial Neoplasia [drug therapy] | Sulfones - therapeutic use | Cervical Intraepithelial Neoplasia - pathology | Cyclooxygenase 2 Inhibitors - administration & dosage | Induction Chemotherapy - methods | Cervical Intraepithelial Neoplasia - drug therapy | Uterine Cervical Neoplasms - drug therapy | Uterine Cervical Neoplasms - pathology | Celecoxib - therapeutic use | Lactones - therapeutic use | Placebos - therapeutic use | Sulfonamides - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Lactones - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Cyclooxygenase 2 Inhibitors - therapeutic use | Adult | Sulfonamides - administration & dosage | Sulfones - administration & dosage
Journal Article
The American journal of medicine, ISSN 0002-9343, 2014, Volume 127, Issue 11, pp. 1075 - 1082.e1
Journal Article
Clinical Lymphoma, Myeloma & Leukemia, ISSN 2152-2650, 2015, Volume 15, Issue 6, pp. 314 - 322
Journal Article
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2018, Volume 379, Issue 17, pp. 1612 - 1620
.... The results indicate that among these patients, the use of VX-445-tezacaftor-ivacaftor to target Phe508del CFTR protein resulted in increased CFTR function in vitro... 
G551D MUTATION | MEDICINE, GENERAL & INTERNAL | TEZACAFTOR-IVACAFTOR | CFTR | Pyrazoles - therapeutic use | Forced Expiratory Volume - drug effects | Humans | Pyrrolidines - administration & dosage | Chloride Channel Agonists - therapeutic use | Male | Aminophenols - therapeutic use | Chloride Channel Agonists - adverse effects | Aminophenols - adverse effects | Pyrrolidines - pharmacology | Pyrrolidines - therapeutic use | Sweat - chemistry | Young Adult | Quinolones - adverse effects | Chlorides - metabolism | Quinolones - therapeutic use | Adult | Benzodioxoles - adverse effects | Female | Benzodioxoles - therapeutic use | Pyrazoles - pharmacology | Pyridines - therapeutic use | Pyridines - administration & dosage | Double-Blind Method | Genotype | Cystic Fibrosis Transmembrane Conductance Regulator - metabolism | Chlorides - analysis | Pyrazoles - administration & dosage | Indoles - adverse effects | Cystic Fibrosis - genetics | Adolescent | Alleles | Cystic Fibrosis Transmembrane Conductance Regulator - genetics | Indoles - therapeutic use | Pyridines - pharmacology | Mutation | Cystic Fibrosis - drug therapy | Drug Combinations | Cystic fibrosis | Ivacaftor | Dosage and administration | Drug therapy | Statistical analysis | Writers | Epithelial cells | Chloride transport | Recovery of function | Patients | Design | Proteins | Genotype & phenotype | Chloride | Collaboration | Conductance | Cystic fibrosis transmembrane conductance regulator | Protein transport | Sweat | Pharmaceuticals
Journal Article